1 enrolling by invitation. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Sudden Infant Death: new trials by email Literature Review of Sudden Infant Death trials Research Report on Sudden Infant Death
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 tividenofusp alfa - Mucopolysaccharidosis II | Phase 2 / Phase 3 | Enrolling by invitation | Denali Therapeutics Inc. | 99 | 2023-09-20 | 2026-10-27 |
Carbohydrate Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Death (1) · Death, Sudden (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Heredodegenerative Disorders, Nervous System (1) · Infant Death (1) · Intellectual Disability (1) · Lysosomal Storage Diseases (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Mucinoses (1) · Mucopolysaccharidoses (1)
Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)
2023 (1)